Telix Pharmaceuticals (ASX: TLX) has launched its initial public offering (IPO) in the US of American Depositary Shares (ADSs), each representing one ordinary share in Telix. The target size of the offering is US$200 million in gross proceeds.
Jefferies, Morgan Stanley, Truist Securities and William Blair are acting as joint book-running managers for the offering.
Telix has applied to list its ADSs on the Nasdaq Global Market (Nasdaq) under the ticker symbol “TLX”. Telix’s ordinary shares are listed, and upon the completing of the Offering, will continue to trade on the Australian Securities Exchange (ASX) under the symbol “TLX”.
Melbourne-headquartered Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical devices.
The company has international operations in the US, Europe (Belgium and Switzerland), and Japan.
It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases.
